Literature DB >> 27704467

Palliative and End-of-Life Care in Myelodysplastic Syndromes.

Myles Nickolich1, Areej El-Jawahri2, Thomas W LeBlanc3,4.   

Abstract

A growing literature demonstrates that MDS is associated with significant impairments in overall quality of life. Given the poor prognosis for many patients with MDS, and the considerable morbidities associated with this disease, there is a critical need to address palliative and end-of-life care needs in this population. However, palliative and end-of-life care issues are under-represented in the MDS literature. In this article, we highlight a growing body of literature that demonstrates unmet palliative and end-of-life care needs in hematologic malignancies, including MDS, and highlight opportunities for further research and quality improvement initiatives to address unmet needs in MDS care.

Entities:  

Keywords:  End-of-life care; Myelodysplastic syndromes; Palliative care; Quality of life

Mesh:

Year:  2016        PMID: 27704467     DOI: 10.1007/s11899-016-0352-z

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  52 in total

Review 1.  The importance of quality of life for patients living with myelodysplastic syndromes.

Authors:  Mary Laudon Thomas; Nicole Crisp; Karen Campbell
Journal:  Clin J Oncol Nurs       Date:  2012-06       Impact factor: 1.027

2.  Costs and quality of life in patients with myelodysplastic syndromes.

Authors:  Carlo Lucioni; Carlo Finelli; Silvio Mazzi; Esther N Oliva
Journal:  Am J Blood Res       Date:  2013-08-19

3.  Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database.

Authors:  Sean A Fletcher; Angel M Cronin; Amer M Zeidan; Oreofe O Odejide; Steven D Gore; Amy J Davidoff; David P Steensma; Gregory A Abel
Journal:  Cancer       Date:  2016-02-23       Impact factor: 6.860

4.  Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists.

Authors:  D Hui; S Bansal; M Park; A Reddy; J Cortes; F Fossella; E Bruera
Journal:  Ann Oncol       Date:  2015-06-03       Impact factor: 32.976

Review 5.  Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

Authors:  Guillermo Garcia-Manero; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

6.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

7.  Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.

Authors:  Fabio Efficace; Gianluca Gaidano; Massimo Breccia; Marianna Criscuolo; Francesco Cottone; Giovanni Caocci; David Bowen; Michael Lübbert; Emanuele Angelucci; Reinhard Stauder; Dominik Selleslag; Uwe Platzbecker; Grazia Sanpaolo; Anna Jonasova; Francesco Buccisano; Giorgina Specchia; Giuseppe A Palumbo; Pasquale Niscola; Chonghua Wan; Huiyong Zhang; Susanna Fenu; Virginia Klimek; Odile Beyne-Rauzy; Khanh Nguyen; Franco Mandelli
Journal:  Br J Haematol       Date:  2014-10-01       Impact factor: 6.998

8.  Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study.

Authors:  David Hui; Neha Didwaniya; Marieberta Vidal; Seong Hoon Shin; Gary Chisholm; Joyce Roquemore; Eduardo Bruera
Journal:  Cancer       Date:  2014-02-18       Impact factor: 6.860

Review 9.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

10.  Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc.

Authors:  Kathleen Heptinstall
Journal:  Oncology (Williston Park)       Date:  2008-02       Impact factor: 2.990

View more
  2 in total

1.  Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study.

Authors:  Jesse D Troy; Carlos M de Castro; Mary Ruth Pupa; Greg P Samsa; Amy P Abernethy; Thomas W LeBlanc
Journal:  J Natl Compr Canc Netw       Date:  2018-03       Impact factor: 11.908

Review 2.  Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology.

Authors:  Ryan J Stubbins; Annabel Francis; Florian Kuchenbauer; David Sanford
Journal:  Curr Oncol       Date:  2022-08-30       Impact factor: 3.109

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.